December 2024

89 percent of patients evaluable for MRD assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months Results add to the overall survival (OS) benefits recently presented, as the first and only cell therapy to significantly extend OS versus standard therapies in mu

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: